Ganfort beats Xalacom

Article

A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

A bimatoprost and timolol fixed combination (Ganfort; Allergan) is more effective at lowering intraocular pressure (IOP) over 12 weeks than latanoprost (Xalacom; Pfizer), according to results presented at the meeting of the European Glaucoma Society (EGS), held June 1–6 in Berlin.

Antonio Martinez of the Instituto Gallego de Oftalmologia, Spain and colleagues conducted a prospective, randomized, evaluator masked, single centre crossover study, in which open angle glaucoma (OAG) patients (n=54; eyes=108) received a once daily evening dose of either Ganfort or Xalacom for 12 weeks, following an initial six week treatment regime of twice daily timolol maleate 0.5%. Patients in the Ganfort arm then received a further 12 weeks of treatment with Xalacom, and patients in the Xalacom arm went on to receive 12 weeks of Ganfort treatment. IOP was measured at baseline, and at weeks six and 12 of each treatment period; mean IOP range across a 12-hour period was also evaluated.

After 12 weeks of treatment, subjects had a mean baseline IOP of 22.0 mmHg; 12 hours post-treatment, patients treated with Ganfort had a mean IOP of 17.7 mmHg whereas patients treated with Xalacom had a mean IOP of 18.5 mmHg. Ganfort subjects showed a mean IOP fluctuation range of 4.8 mmHg; in Xalacom-treated patients, the range was 5.9 mmHg.

Thus the researchers concluded that, whilst both treatments are efficacious, Ganfort is slightly more effective than Xalacom in reducing IOP in OAG subjects.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.